BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20164240)

  • 1. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
    Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
    Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
    Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
    Perrone F; Da Riva L; Orsenigo M; Losa M; Jocollè G; Millefanti C; Pastore E; Gronchi A; Pierotti MA; Pilotti S
    Neuro Oncol; 2009 Dec; 11(6):725-36. PubMed ID: 19246520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
    de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
    Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
    Yu L; Saile K; Swartz CD; He H; Zheng X; Kissling GE; Di X; Lucas S; Robboy SJ; Dixon D
    Mol Med; 2008; 14(5-6):264-75. PubMed ID: 18231572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
    Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
    Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
    Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
    Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent activation of EGFR in advanced chordomas.
    Dewaele B; Maggiani F; Floris G; Ampe M; Vanspauwen V; Wozniak A; Debiec-Rychter M; Sciot R
    Clin Sarcoma Res; 2011 Jul; 1(1):4. PubMed ID: 22613809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to sunitinib malate in advanced alveolar soft part sarcoma.
    Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
    Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
    Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
    Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
    Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
    J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
    Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
    J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
    Negri T; Virdis E; Brich S; Bozzi F; Tamborini E; Tarantino E; Jocollè G; Cassinelli G; Grosso F; Sanfilippo R; Casalini P; Greco A; Pierotti MA; Pilotti S
    Clin Cancer Res; 2010 Jul; 16(14):3581-93. PubMed ID: 20522586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stretch-induced mitogen-activated protein kinase activation in lung fibroblasts is independent of receptor tyrosine kinases.
    Boudreault F; Tschumperlin DJ
    Am J Respir Cell Mol Biol; 2010 Jul; 43(1):64-73. PubMed ID: 19684308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.
    Shalaby AA; Presneau N; Idowu BD; Thompson L; Briggs TR; Tirabosco R; Diss TC; Flanagan AM
    Mod Pathol; 2009 Aug; 22(8):996-1005. PubMed ID: 19407855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
    Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.